HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s

Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with

Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial paye

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-

Real-world analysis of three years of closed claims data from Symphony Health focused on the third y

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer

Agreement with leading group purchasing organization (GPO) provides access to approximately 35 milli

TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy ra

Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field

TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significan

The publication reports findings from a single-center, randomized, open-label, multiple-dose, parall

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a

Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models an

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptio

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In pos

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the

Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators s

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3

TNXP announced updates on TNX-4800, a long-acting mAb targeting Lyme disease. Seeking FDA meeting in

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemothera

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major d

Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commerci

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a ful

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children

Tonix anticipates filing the IND application in the fourth quarter of 2025TNX-102 SL is a potential

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: ef

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. l